GlassScriptPhysician profile
Audra Ballash
NPI 1558870139
$6,191.10
in general payments reported to CMS, 2019-2025
32 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.37 · 2022: $756 · 2023: $1,143 · 2024: $1,920 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,271.23 |
| Education | $113.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,199.87 | 2021-2025 | |
| Janssen Biotech, INC. | $732.47 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $404.81 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $350.77 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.12 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $257.85 | 2023-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $186.23 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $180.29 | 2022-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $176.54 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $168.10 | 2023-2025 | |
| Axonics, INC. | $142.90 | 2023-2024 | Axonics |
| Phathom Pharmaceuticals, INC. | $121.80 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $117.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $108.14 | 2024-2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $100.43 | 2023-2024 | Linzess |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $93.70 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $86.42 | 2022 | |
| Lucid Diagnostics INC. | $60.00 | 2023 | |
| Alnylam Pharmaceuticals INC. | $58.28 | 2025 | Givlaari |
| Celltrion USA INC. | $50.91 | 2024 | Zymfentra, Vegzelma |
| Novo Nordisk INC | $47.52 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $44.95 | 2024 | Iqirvo |
| Boston Scientific Corporation | $44.66 | 2025 | Axonics |
| Genzyme Corporation | $43.63 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.91 | 2023 | Andexxa |
| Nestle Healthcare Nutrition INC. | $24.32 | 2021 | |
| Merck Sharp & Dohme LLC | $24.06 | 2024 | Dificid |
| Amgen INC. | $19.95 | 2025 | Uplizna |
| Teleflex LLC | $18.76 | 2024 | Solesta |
| Medtronic, INC. | $18.44 | 2022 | |
| Evoke Pharma, INC. | $16.65 | 2022 | |
| Organon LLC | $6.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Ballash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.